Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

lts of operations could be adversely affected. These factors, and other factors, including, but not limited to those described in ViroPharma's annual report on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission during 2008, could cause future results to differ materially from the expectations expressed in this press release. The forward-looking statements contained in this press release may become outdated over time. ViroPharma does not assume any responsibility for updating any forward-looking statements.



                            VIROPHARMA INCORPORATED
                        Selected Financial Information


    Consolidated Statements of          Three months         Twelve months
     Operations:                           ended                ended
                                        December 31,          December 31,
    (in thousands, except per           -----------           -----------
     share data)                       2008      2007       2008       2007
                                       ----      ----       ----       ----

    Revenue:
    Net product sales                $50,020   $47,696   $232,307   $203,770
                                      ------    ------    -------    -------
    Revenue                           50,020    47,696    232,307    203,770
                                      ------    ------    -------    -------
    Costs and Expenses:
    Cost of sales (excluding
     amortization of product rights)   2,110     2,034      8,874      8,934
    Research and development          21,197    12,504     66,280     35,869
    Selling, general and
     administrative                   22,357    12,710     65,424     37,051
    Intangible amortization            5,505     1,401     10,809      6,120
    Impairment of fixed assets
     held for sale                     2,265         -      2,265          -
              
'/>"/>
SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... -- ECC West Africa, LLC (ECC) signed a contract in ... Hospital (UCH) Ibadan Board of Management for the first ... and operate and maintain a new, state-of-the-art Cancer Institute ... first of the 4-phase project, ECC will conduct feasibility ... Ibadan intends to finance and develop the Cancer Institute ...
(Date:7/24/2014)... natural and synthetic processes prefer to settle into ... energyit is within the realm of non-equilibrium conditions ... changes in energy and phases, such as temperature ... allow humans to regulate their body temperature, airplanes ... seismic activity. , But even though these ...
(Date:7/24/2014)... , July 24, 2014  CorMedix Inc. ... developing and commercializing therapeutic products for the prevention ... announces receipt of notice on July 18, 2014 ... NYSE-MKT has accepted the CorMedix plan to regain ... As a result, the NYSE-MKT is continuing the ...
(Date:7/24/2014)... 2014 1000 balances – 4 steps ... customers’ weighing needs and expertly narrows down the mass ... scales or even terminals. , First, select the ... (or select readability instead) and define the accuracy – ... criteria narrows down the list to models that fit ...
Breaking Biology Technology:ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2New approach to form non-equilibrium structures 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3
... than a year after Chippewa Valley Technical College ... Administration has approved a $1.5 million grant to help ... ,The grant will cover part of the cost of ... create an estimated 650 jobs and generate $30 million ...
... Day birthing of new products, or simply the last rush to ... busy day for product news. In fact, two DEMO alumni - ... - are delivering significant new functionality to their faithful customers. ... smart phone. The newest member of the Treo family is based ...
... - By several measures, these should be heady days ... manufacturing jobs were lost, the economy is back, manufacturing revenue ... there is a sense of unease linked to withering competitive ... of what their American counterparts earn, where manufacturers have a ...
Cached Biology Technology:Two DEMO alumni make big product splashes 2Two DEMO alumni make big product splashes 3Manufacturers advised to redesign customer relations 2Manufacturers advised to redesign customer relations 3
(Date:7/24/2014)... 2014 /PRNewswire-iReach/ -- The Geneva Healthcare Suite, an innovative ... cut emergency room wait times by an average of ... Center, according to a recent study published in the ... using the suite to access data from incoming patients, ... "Using Geneva,s technology platform we have been able ...
(Date:7/24/2014)... by 45% on average over a 35 year period ... on the impact of humans on declining animal numbers. ... such as insects, spiders, crustaceans, slugs and worms bring ... for crops, decomposition for nutrient cycling, water filtration and ... and led by UCL, Stanford and UCSB, focused ...
(Date:7/24/2014)... Imagine a smog-free Los Angeles, where electric cars ply ... run on heat from beneath the earth, from howling ... new Stanford study finds that it is technically and ... one powered by clean, renewable energy. Published in ... sustainable, inexpensive and reliable energy supply in California that ...
Breaking Biology News(10 mins):UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3Stanford study shows how to power California with wind, water and sun 2Stanford study shows how to power California with wind, water and sun 3Stanford study shows how to power California with wind, water and sun 4
... is showing multiple benefits from restoration efforts, newly published ... increased the abundance and diversity of submerged aquatic vegetation ... during the 18-year field study. Since 1990, the ... doubled, the area covered by native SAV has increased ...
... prominent speakers have been added to the slate ... Military Medicine Symposium: Advancing Public-Private Partnerships, on September ... Washington, D.C. The event is a premier opportunity ... to come together to discuss medical partnerships to ...
... than a health hazard according to scientists from The University ... Medicine and Science have discovered powerful antibiotic properties in the ... treatments for multi-drug resistant bacterial infections. They found that the ... were able to kill more than 90 per cent of ...
Cached Biology News:Potomac River: 10-fold increase in native submerged vegetation reflects improved water quality 2Sutherland and Berglass to keynote USU-HJF Military Medicine Symposium 2Sutherland and Berglass to keynote USU-HJF Military Medicine Symposium 3Cockroach brains could be rich stores of new antibiotics 2
... The Zero Blunt ... for Sequencing is designed ... sequencing of blunt-end PCR ... provides 5-minute TOPO Cloning ...
Recommend to use at 1000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.)...
Recombinant Human CCL21/6Ckine (Mucin Stalk Chimera)...
One-step, microplate or cuvet, colorimetric, detection range 0.78 ug/dL to 65 ug/dL Zn in serum, plasma, urine, saliva etc. Procedure: 10 min....
Biology Products: